product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
IL-17RD/SEF Antibody (001) [DyLight 488]
catalog :
NBP2-89540G
quantity :
0.1 ml
price :
539 USD
clonality :
monoclonal
host :
domestic rabbit
conjugate :
DyLight488
clone name :
001
reactivity :
human
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP2-89540G
SKU :
NBP2-89540G
product name :
IL-17RD/SEF Antibody (001) [DyLight 488]
sizes available :
0.1 ml
description :
The IL-17RD/SEF Antibody (001) [DyLight 488] from NBP2-89540G is a 6.7e-05 antibody to . This antibody reacts with human.
target :
IL-17RD/SEF
category :
Primary Antibodies
buffer :
50mM Sodium Borate
clonality :
Monoclonal
clone :
001
conjugate :
DyLight 488
all_available conjugate :
mFluor Violet 500 SE;DyLight 488
dilution :
Sandwich ELISA Capture
host :
Rabbit
immunogen :
This antibody was obtained from a rabbit immunized with purified, recombinant Human IL-17RD/SEF (Accession#: NP_060033.3; Met1-Arg299).
isotype :
IgG
purity :
Protein A purified
species :
Human
gene symbol :
IL17RD
applications :
Sandwich ELISA Capture
extended description :
Recombinant Monoclonal Antibody
USD :
539 USD
product details :
Recombinant Monoclonal Antibody
alt names :
FLJ35755, IL-17RDIL-17 receptor D, IL17Rhom, IL17RLMDKFZp434N1928, interleukin 17 receptor D, interleukin-17 receptor D, Interleukin-17 receptor-like protein, MGC133309, Sef homolog, SEFhSef
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments
